Literature DB >> 17541998

The role of corticosteroids in muscular dystrophy: a critical appraisal.

Corrado Angelini1.   

Abstract

Over the years various steroid trials have been conducted in Duchenne muscular dystrophy (DMD). In children who are still able to walk as well as in those who are wheelchair-bound, corticosteroids have been found to stabilize muscle strength for a period of time. Controlled clinical observations have shown that some boys remain ambulatory for years longer than reported in natural history data. The two main steroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different side-effect profiles; for instance, deflazacort causes less weight gain. The exact mechanism by which steroids slow the dystrophic process is under investigation. DMD children treated long term also seem to develop other complications of the condition less frequently. For instance, they develop respiratory insufficiency later and have fewer cardiac symptoms. The therapeutic value of corticosteroids is limited, but these drugs represent the best treatment option currently available.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541998     DOI: 10.1002/mus.20812

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  63 in total

1.  Dystrophin immunity in Duchenne's muscular dystrophy.

Authors:  Jerry R Mendell; Katherine Campbell; Louise Rodino-Klapac; Zarife Sahenk; Chris Shilling; Sarah Lewis; Dawn Bowles; Steven Gray; Chengwen Li; Gloria Galloway; Vinod Malik; Brian Coley; K Reed Clark; Juan Li; Xiao Xiao; Jade Samulski; Scott W McPhee; R Jude Samulski; Christopher M Walker
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

2.  Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Authors:  Ida Luisa Rotundo; Stefania Faraso; Elvira De Leonibus; Gerardo Nigro; Carmen Vitiello; Alessio Lancioni; Daniele Di Napoli; Sigismondo Castaldo; Vincenzo Russo; Fabio Russo; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

3.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

4.  Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy.

Authors:  Sunita Mathur; Donovan J Lott; Claudia Senesac; Sean A Germain; Ravneet S Vohra; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  Arch Phys Med Rehabil       Date:  2010-07       Impact factor: 3.966

5.  Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose-dependent manner through modulation of dystrophin.

Authors:  Gianna Móes Albuquerque-Pontes; Heliodora Leão Casalechi; Shaiane Silva Tomazoni; Andrey Jorge Serra; Cheila de Sousa Bacelar Ferreira; Rodrigo Barbosa de Oliveira Brito; Brunno Lemes de Melo; Adriane Aver Vanin; Kadma Karênina Damasceno Soares Monteiro; Humberto Dellê; Lucio Frigo; Rodrigo Labat Marcos; Paulo de Tarso Camillo de Carvalho; Ernesto Cesar Pinto Leal-Junior
Journal:  Lasers Med Sci       Date:  2017-12-05       Impact factor: 3.161

6.  Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice.

Authors:  Guy L Odom; Paul Gregorevic; James M Allen; Eric Finn; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

7.  Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation.

Authors:  Joseph J Belanto; Silvia V Diaz-Perez; Clara E Magyar; Michele M Maxwell; Yasemin Yilmaz; Kasey Topp; Guney Boso; Catriona H Jamieson; Nicholas A Cacalano; Christina A M Jamieson
Journal:  Neuromuscul Disord       Date:  2010-01-18       Impact factor: 4.296

8.  Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study.

Authors:  Merel Jansen; Imelda Jm de Groot; Nens van Alfen; Alexander Ch Geurts
Journal:  BMC Pediatr       Date:  2010-08-06       Impact factor: 2.125

Review 9.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

10.  Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program.

Authors:  Alexander Morrison-Nozik; Priti Anand; Han Zhu; Qiming Duan; Mohamad Sabeh; Domenick A Prosdocimo; Madeleine E Lemieux; Nikolai Nordsborg; Aaron P Russell; Calum A MacRae; Anthony N Gerber; Mukesh K Jain; Saptarsi M Haldar
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.